Recommendation of the President – Talzenna (talazoparib)
On 20 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 155/2024 on the appraisal Talzenna (talazoparib) under the drug program: “Treatment of patients with prostate cancer (ICD-10: C61)”